CMChristoph Matti

Christoph Matti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christoph Matti has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Base Editing of Hematopoietic Stem Cells Corrects Gain-of-Function Mutations in APDS

    by Katharine Orf, Robert Torrance, Christoph Matti, Nathan White, Leqi Tang, Chunan Liu, Adriana S Albuquerque, Adrian J Thrasher, Sara Benedetti, Klaus Okkenhaug, et al.

    Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase  enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.

  • Open Access

    Functional restoration of immune defects in STAT1 gain-of-function disease after stem cell gene editing

    by Robert Torrance, Katharine Orf, Nathan White, Christoph Matti, Alexander J. McKenna, Andrea Cosentino, Gabriele Casirati, Adriana S. Albuquerque, Adrian J. Thrasher, Pietro Genovese, et al.

    Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.


  • Open Access

    Fusion of Complement Fragment C3d Enhances Germinal Center Responses to HIV-1 Envelope Glycoproteins

    by Marlon de Gast, Sara Hernández-Pérez, Arpan Pradhan, Sabine Kruijer, Wouter Olijhoek, Isabel J. L. Baken, Christoph Matti, Martijn Breeuwsma, Zhang Sung Tean, Willemijn J. C. van Keizerswaard, et al.

    Eliciting sustained germinal center (GC) responses is critical for the development of an effective HIV-1 vaccine, yet HIV-1 envelope glycoprotein (Env) immunogens often fail to elicit GC responses required for the maturation of cognate B cells that secrete broadly neutralizing antibodies (bNAbs). Effective antigen recognition is important for initial B cell priming, activation, and GC engagement. Since complement opsonization contributes to antigen recognition, we investigated whether C3d fusion could enhance the GC response of the stabilized HIV-1 Env immunogen based on a consensus sequence (ConM Env). Our results demonstrate that ConM Env-C3d induced potent HIV-specific B cell activation in vitro compared to ConM Env alone. We also observed that the C3d fusion enhanced antigen presentation by human tonsil-derived follicular dendritic cells (FDCs) to HIV-specific B cell lines. Moreover, mouse immunization studies combining ConM Env-C3d with the AddaS03 adjuvant revealed significantly enhanced early GC formation and prolonged antigen display and retention on FDCs for up to 56 days, highlighting improved antigen persistence within GCs. These immunological enhancements, including a more focused early antibody response, correlated with improved virus neutralization. Additionally, we observed sex-based differences in immune responses, with female mice showing stronger antibody responses and enhanced antigen retention compared to males. These findings suggest that C3d fusion can enhance GC engagement and improve the immunogenicity of HIV-1 vaccines.

  • Open Access

    Mechanosensitive ACKR4 scavenges CCR7 chemokines to facilitate T cell de-adhesion and passive transport by flow in inflamed afferent lymphatics

    by Mona C. Friess, Ioannis Kritikos, Philipp Schineis, Jessica Danielly Medina-Sanchez, Anastasia-Olga Gkountidi, Angela Vallone, Elena C. Sigmund, Corina Schwitter, Martina Vranova, Christoph Matti, et al.


  • Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases

    by Monica Patel, Christoph Matti, Natasha L. Grimsey, Daniel F. Legler, Jonathan A. Javitch, David B. Finlay, Michelle Glass

    Background and Purpose: The cannabinoid CB2 receptor (CB2) is a promising therapeutic target for modulating inflammation. However, little is known surrounding the mechanisms underpinning CB2 desensitisation and regulation, particularly the role of GPCR kinases (GRKs). Here, we evaluated the role of six GRK isoforms in β‐arrestin recruitment to CB2. Mutagenesis of several distal C‐terminal aspartic acid residues was also performed in an attempt to delineate additional structural elements involved in the regulation of CB2.Experimental Approach: In CB2‐expressing HEK 293 cells, β‐arrestin translocation was measured using real‐time BRET assays. G protein dissociation BRET assays were performed to assess the activation and desensitisation of CB2 in the presence of β‐arrestin 2.Key Results: Overexpression of GRK isoforms 1–6 failed to considerably improve translocation of either β‐arrestin 1 or β‐arrestin 2 to CB2. Consistent with this, inhibition of endogenous GRK2/3 did not substantially reduce β‐arrestin 2 translocation. Mutagenesis of C‐terminal aspartic acid residues resulted in attenuation of β‐arrestin 2 translocation, which translated to a reduction in desensitisation of G protein activation.Conclusion and Implications: Our findings suggest that CB2 does not adhere to the classical GPCR regulatory paradigm, entailing GRK‐mediated and β‐arrestin‐mediated desensitisation. Instead, C‐terminal aspartic acid residues may act as phospho‐mimics to induce β‐arrestin activation. This study provides novel insights into the regulatory mechanisms of CB2, which may aid in our understanding of drug tolerance and dependence.


  • Open Access

    A Versatile Toolkit for Semi-Automated Production of Fluorescent Chemokines to Study CCR7 Expression and Functions

    by Marc Artinger, Christoph Matti, Oliver J. Gerken, Christopher T. Veldkamp, Daniel F. Legler

    Chemokines guide leukocyte migration in different contexts, including homeostasis, immune surveillance and immunity. The chemokines CCL19 and CCL21 control lymphocyte and dendritic cell migration and homing to lymphoid organs. Thereby they orchestrate adaptive immunity in a chemokine receptor CCR7-dependent manner. Likewise, cancer cells that upregulate CCR7 expression are attracted by these chemokines and metastasize to lymphoid organs. In-depth investigation of CCR7 expression and chemokine-mediated signaling is pivotal to understand their role in health and disease. Appropriate fluorescent probes to track these events are increasingly in demand. Here, we present an approach to cost-effectively produce and fluorescently label CCL19 and CCL21 in a semi-automated process. We established a versatile protocol for the production of recombinant chemokines harboring a small C-terminal S6-tag for efficient and site-specific enzymatic labelling with an inorganic fluorescent dye of choice. We demonstrate that the fluorescently labeled chemokines CCL19-S6Dy649P1 and CCL21-S6Dy649P1 retain their full biological function as assessed by their abilities to mobilize intracellular calcium, to recruit β-arrestin to engaged receptors and to attract CCR7-expressing leukocytes. Moreover, we show that CCL19-S6Dy649P1 serves as powerful reagent to monitor CCR7 internalization by time-lapse confocal video microscopy and to stain CCR7-positive primary human and mouse T cell sub-populations.


  • Open Access

    Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7

    by Barbara D. Jakobs, Lisa Spannagel, Vladimir Purvanov, Edith Uetz-Von Allmen, Christoph Matti, Daniel F. Legler

    The chemokine receptor CCR7 plays a pivotal role in health and disease. In particular, CCR7 controls homing of antigen-bearing dendritic cells and T cells to lymph nodes, where adaptive immune responses are initiated. However, CCR7 also guides T cells to inflamed synovium and thereby contributes to rheumatoid arthritis and promotes cancer cell migration and metastasis formation. Nanobodies have recently emerged as versatile tools to study G-protein-coupled receptor functions and are being tested in diagnostics and therapeutics. In this study, we designed a strategy to engineer novel nanobodies recognizing human CCR7. We generated a nanobody library based on a solved crystal structure of the nanobody Nb80 recognizing the β2-adrenergic receptor (β2AR) and by specifically randomizing two segments within complementarity determining region 1 (CDR1) and CDR3 of Nb80 known to interact with β2AR. We fused the nanobody library to one half of split-YFP in order to identify individual nanobody clones interacting with CCR7 fused to the other half of split-YFP using bimolecular fluorescence complementation. We present three novel nanobodies, termed Nb1, Nb5, and Nb38, that recognize human CCR7 without interfering with G-protein-coupling and downstream signaling. Moreover, we were able to follow CCR7 trafficking upon CCL19 triggering using Nb1, Nb5, and Nb38.


  • Open Access

    Fluorescently Tagged CCL19 and CCL21 to Monitor CCR7 and ACKR4 Functions

    by Vladimir Purvanov, Christoph Matti, Guerric P. B. Samson, Ilona Kindinger, Daniel F. Legler

    Chemokines are essential guidance cues orchestrating cell migration in health and disease. Cognate chemokine receptors sense chemokine gradients over short distances to coordinate directional cell locomotion. The chemokines CCL19 and CCL21 are essential for recruiting CCR7-expressing dendritic cells bearing pathogen-derived antigens and lymphocytes to lymph nodes, where the two cell types meet to launch an adaptive immune response against the invading pathogen. CCR7-expressing cancer cells are also recruited by CCL19 and CCL21 to metastasize in lymphoid organs. In contrast, atypical chemokine receptors (ACKRs) do not transmit signals required for cell locomotion but scavenge chemokines. ACKR4 is crucial for internalizing and degrading CCL19 and CCL21 to establish local gradients, which are sensed by CCR7-expressing cells. Here, we describe the production of fluorescently tagged chemokines by fusing CCL19 and CCL21 to monomeric red fluorescent protein (mRFP). We show that purified CCL19-mRFP and CCL21-mRFP are versatile and powerful tools to study CCR7 and ACKR4 functions, such as receptor trafficking and chemokine scavenging, in a spatiotemporal fashion. We demonstrate that fluorescently tagged CCL19 and CCL21 permit the visualization and quantification of chemokine gradients in real time, while CCR7-expressing leukocytes and cancer cells sense the guidance cues and migrate along the chemokine gradients.